We Work for Health | WA (@WWFH_WA) header
We Work for Health | WA (@WWFH_WA) profile picture

We Work For Health Washington is a grassroots coalition showcasing the tremendous impact the life sciences industry brings to the state of Washington.

Washington
Joined March 2013
"The administration has legitimate reasons to guard against investments that could strengthen China's military capabilities...But ordinary pharmaceutical research should not be treated as a national security threat merely because it originates in China." forbes.com/sites/sallypipes/…
10
COINS is "meant to enhance our national security by preventing American resources from building up China’s already growing biotech capabilities...the proposal is so broad that it could hurt American biotech companies far more than it hurts Chinese ones." fortune.com/2026/11/12/roy-b…
14
"What could proposed restrictions on U.S. investment in Chinese biotechnology mean for the 194 million Americans living with chronic conditions?" More on the impact of the COINS Act: youtube.com/watch?v=K1yt-LcM…
28
"Reliable #IP protections reduce investment risk in an industry defined by long timelines and high failure rates, while allowing specialized companies to focus on speeding up the broader drug development pipeline." thedailyrecord.com/2026/10/2…
14
"Prior authorization makes money for insurers. Every delay and every denial can mean care that never gets paid for. Companies don’t easily give up tools that pad their bottom line." healthcareuncovered.substack…
1
1
26
"Can America strengthen its biotech leadership by restricting China—or should it focus on making the United States the best place in the world to develop new medicines?" Tune in to learn more: youtube.com/watch?v=ijDqz8Md…
13
"We need to remove the barriers patients face when trying to access their medicines, not institute pricing policies like MFN that are proven to make these problems worse. We should fix insurance and protect the innovation we depend on to save lives." nopatientleftbehind.org/medi…
14
"The United States accounts for about 75% of global pharmaceutical profits, despite representing roughly 5% of the world’s population...That imbalance matters because new medicines benefit patients worldwide." truthonthemarket.com/2026/10…
11
"Price controls in Europe have coincided with a gradual contraction of the continent’s biotech sector and more limited patient access to new medicines. Policymakers must approach any similar policy shift here clear-eyed about the potential trade-offs." nationalreview.com/2026/10/a…
20
"If China becomes the global biotech leader, it will give Beijing significant leverage over America’s health and security in future crises. It’ll also weaken America’s ability to shape the future of medicine, profoundly damaging our economy." statnews.com/2026/09/30/chin…
12
"Insurers rigged the system, counting billions in overhead, marketing and other costs as ‘medical’ expenses. We need real transparency to make sure health dollars go to patients — not just insurers’ bottom line." dailycaller.com/2026/09/17/i…
10
"The lesson from the #IRA and other countries around the world is simple: Government drug price controls do not improve patient access. In many cases, price controls create incentives to ration care and empower government bureaucrats." thehill.com/opinion/healthca…
18
"Drawing on nearly three decades of AUTM licensing survey data, the report finds that Bayh-Dole-enabled technology transfer has helped launch more than 19,000 startups and 17,000 new products." More in the newly released report: bayhdolecoalition.org/wp-con…
12